Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

DF1001

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dragonfly Therap

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Zercepac (trastuzumab biosimilar) (8)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 expression	Lung Cancer	HER-2 expression	Lung Cancer	DF1001 Sensitive: C2 – Inclusion Criteria DF1001 Sensitive : C2	DF1001 Sensitive: C2 – Inclusion Criteria DF1001 Sensitive : C2
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	DF1001 Sensitive: C2 – Inclusion Criteria DF1001 Sensitive : C2	DF1001 Sensitive: C2 – Inclusion Criteria DF1001 Sensitive : C2